Ibudilast for the treatment of drug addiction and other neurological conditions
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Ibudilast is a small molecular weight, orally administered compound that was originally developed and approved in Japan over 20 years ago for bronchial asthma and poststroke complication (subsequently defined as poststroke dizziness in 2002). Over the last 10 years, there has been substantial progress in better understanding ibudilast’s molecular and cellular actions including macrophage migration inhibitory factor inhibition, phosphodiesterase inhibition and attenuation of activated glia. Moreover, its potential safety and efficacy in new neurological indications has been explored via animal models and Phase I and II clinical studies. Phase II clinical trials have now initiated in methamphetamine and other drug addictions, progressive multiple sclerosis and pain. A current model of ibudilast target action and a review of its translational progress and prospects as a new medication in these disorders is described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methamphetamine causes microglial activation in the brains of human abusers
Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., Iwata, Y., Tsuchiya, K. J., Suda, S., Suzuki, K., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1179-08.2008 · Cited by 381
Schwarz, J. M., Hutchinson, M. R., & Bilbo, S. D. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3297-11.2011 · Cited by 203
Bell, R. L., Lopez, M. F., Cui, C., Egli, M., Johnson, K. W., Franklin, K. M., & Becker, H. C. (2015) · Addiction Biology · doi:10.1111/adb.12106 · Cited by 138
Self-citationBeardsley, P. M., Shelton, K. L., Hendrick, E., & Johnson, K. W. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.010 · Cited by 97
Self-citation
Research works printed but not linked: 45
- 10.3109/02770909209048938 · DOI · Paper page
- Fukuyama, 1993, Neurol. Res., 15, 169, 10.1080/01616412.1993.11740130 · doi:10.1080/01616412.1993.11740130
- 10.1517/13543784.16.7.935 · DOI · Paper page
- 10.1517/14656560903426189 · DOI · Paper page
- 10.1212/WNL.0b013e3181d7d651 · DOI · Paper page
- 10.1017/S1740925X0700035X · DOI · Paper page
- 10.3109/00498250903254340 · DOI
- 10.1073/pnas.1002716107 · DOI · Paper page
- 10.1016/j.ejphar.2006.02.053 · DOI
- 10.1074/jbc.M112.385070 · doi:10.1074/jbc.m112.385070
- 10.1016/S0006-8993(99)01666-2 · DOI
- 10.1016/j.bbi.2008.09.012 · DOI · Paper page
- 10.1038/nrd1251 · DOI · Paper page
- Romero-Sandoval, 2008, Curr. Opin. Investig. Drugs., 9, 726
- 10.1016/j.bbi.2008.09.004 · DOI · Paper page
- Bar-Or, 2010, Int.J. MS Care, 12, 16
- 10.1038/jcbfm.2009.261 · DOI · Paper page
- 10.1007/s00213-010-2014-5 · DOI · Paper page
- 10.1196/annals.1441.032 · DOI · Paper page
- 10.1016/j.drudis.2012.12.013 · DOI
- 10.1016/j.neuropharm.2003.09.009 · DOI · Paper page
- 10.1111/j.1530-0277.2011.01722.x · DOI · Paper page
- 10.1016/j.ejphar.2013.01.016 · DOI · Paper page
- 10.1016/j.bbi.2009.01.014 · DOI · Paper page
- Bell, 2013, Addict. Biol.
- 10.1016/j.genhosppsych.2009.12.005 · DOI
- 10.1212/WNL.0b013e3181d6b165 · doi:10.1212/wnl.0b013e3181d6b165
- Ellis, 2008, Soc. Neuroscience
- 10.1007/s00401-008-0476-x · DOI
- 10.1097/ALN.0b013e31820a4bf3 · DOI
- 10.1016/S0165-5728(98)00251-3 · DOI
- 10.1186/1742-2094-2-10 · DOI
- Powell, 2005, J. Immunol., 175, 5611, 10.4049/jimmunol.175.9.5611 · DOI
- 10.1096/fj.10-162347 · DOI
- 10.1038/jcbfm.2010.194 · DOI · Paper page
- 10.1111/j.1365-2125.2008.03270.x · DOI · Paper page
- 10.1007/s11065-007-9031-0 · DOI · Paper page
- ComerS, Saccone P, Johnson KW. A drug candidate for improving opioid analgesia and attenuating dependence and tolerance: an exploratory trial of ibudilast in morphine withdrawal and analgesia in heroin addicts. 80(Meeting Abstracts 1) (2013). · doi:10.1212/wnl.80.7_supplement.p07.183
- 10.1191/1352458504ms1070oa · DOI
- 10.1177/0333102412467512 · DOI
- 10.1016/j.mehy.2008.09.048 · DOI
- 10.1089/neu.2011.2273 · DOI
- 10.1016/j.mehy.2012.08.013 · DOI
- Rodgers, 2013, J. Neurotrauma.
- 10.1096/fj.12-214643 · DOI
Cited by
Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker
Yang, Z., & Wang, K. K. W. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.04.003 · Cited by 1,050
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox, R. J., Coffey, C. S., Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803583 · Cited by 286
Self-citationNovel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“As increases in inflammation are seen in AUD [186], the effects of ibudilast in treating AUD are thought to be driven by its anti-inflammatory and proneurotrophic qualities [187].”
BackgroundRay, L. A., Bujarski, S., Shoptaw, S., Roche, D. J., Heinzerling, K., & Miotto, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.10 · Cited by 118
A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Celik, M., Gold, M. S., & Fuehrlein, B. (2024) · Brain Sciences · doi:10.3390/brainsci14030294 · Cited by 25
Metadata
- Authors
- Johnson, K. W., Matsuda, K., & Iwaki, Y.
- Venue
- Clinical Investigation
- Publisher
- OMICS Publishing Group
- Published
- 2014-03
- Volume
- 4
- Issue
- 3
- Pages
- 269-279
- ISSN
- 2041-6792 (ISSN-L)
- 2041-6806
- OpenAlex
- W2124142446
- Cited by
- 29
- References
- 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibudilast for the treatment of drug addiction and other neurological conditions. https://app.cochat.ai/papers/10.4155/cli.14.8
- The paper
- Johnson, K. W., Matsuda, K., & Iwaki, Y. (2014). Ibudilast for the treatment of drug addiction and other neurological conditions. Clinical Investigation. https://doi.org/10.4155/cli.14.8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.